Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 65 of 65 matching drugs for MRPL22 — including drugs targeting any of its 89 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
everolimus MTOR SSL via MTOR yes 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
aee788, everolimus MTOR SSL via MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MTOR SSL via MTOR 1
alpelisib, everolimus, exemestane MTOR SSL via MTOR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib MTOR SSL via MTOR 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus MTOR SSL via MTOR 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus PGD SSL via PGD 1
bevacizumab, everolimus, octreotide acetate MTOR SSL via MTOR 1
bevacizumab, temsirolimus MTOR SSL via MTOR 1
conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus MTOR SSL via MTOR 1
cytoreductive surgery, perifosine, temsirolimus MTOR SSL via MTOR 1
erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study MTOR SSL via MTOR 1
everolimus, archival tissue analysis MTOR SSL via MTOR 1
everolimus, gefitinib MTOR SSL via MTOR 1
everolimus, laboratory biomarker analysis MTOR SSL via MTOR 1
everolimus, lde 225 MTOR SSL via MTOR 1
everolimus, placebo MTOR SSL via MTOR 1
everolimus, sorafenib MTOR SSL via MTOR 1
everolimus, temozolomide, microarray analysis, immunohistochemistry staining method MTOR SSL via MTOR 1
everolimus, temozolomide, radiation MTOR SSL via MTOR 1
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging MTOR SSL via MTOR 1
fluorouracil, leucovorin calcium, oxaliplatin, everolimus, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis MTOR SSL via MTOR 1
intestinal, multivisceral or modified multivisceral transplantation, alemtuzumab, tacrolimus, sirolimus MTOR SSL via MTOR 1
laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery MTOR SSL via MTOR 1
laboratory biomarker analysis, pharmacological study, temsirolimus, trebananib MTOR SSL via MTOR 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil MTOR SSL via MTOR 1
metformin xr, delayed metformin, sirolimus MTOR SSL via MTOR 1
p-muc1c-allo1 car-t cells, rimiducid MTOR SSL via MTOR 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) MTOR SSL via MTOR 1
pasireotide lar, everolimus, pasireotide lar and everolimus combination MTOR SSL via MTOR 1
pentostatin, sirolimus, cyclophosphamide, allogeneic hematopoietic stem cell transplant (hsct), th2 rapa cells, donor lymphocyte harvest, induction therapy, gvhd prophylaxis, donor hematopoietic stem cell harvest MTOR SSL via MTOR 1
pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, temsirolimus, temozolomide MTOR SSL via MTOR 1
radiation therapy, temozolomide, bevacizumab, bevacizumab, everolimus MTOR SSL via MTOR 1
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine PGD SSL via PGD 1
ribociclib, everolimus MTOR SSL via MTOR 1
ridaforolimus, mk-0752, mk-2206 MTOR SSL via MTOR 1
ryz101, everolimus, sunitinib, octreotide, lanreotide MTOR SSL via MTOR 1
sirolimus MTOR SSL via MTOR 1
sirolimus, placebo MTOR SSL via MTOR 1
sirolimus, vandetanib MTOR SSL via MTOR 1
sorafenib tosylate, erlotinib hydrochloride, tipifarnib, temsirolimus MTOR SSL via MTOR 1
sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study MTOR SSL via MTOR 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide MTOR SSL via MTOR 1
tacrolimus, methotrexate, sirolimus MTOR SSL via MTOR 1
temozolomide, temsirolimus MTOR SSL via MTOR 1
temsirolimus, bevacizumab MTOR SSL via MTOR 1
temsirolimus, docetaxel MTOR SSL via MTOR 1
temsirolimus, laboratory biomarker analysis, pharmacological study MTOR SSL via MTOR 1
temsirolimus, pegylated liposomal doxorubicin MTOR SSL via MTOR 1
temsirolimus, pharmacological study, cytokine levels MTOR SSL via MTOR 1
temsirolimus, pharmacological study, laboratory biomarker analysis MTOR SSL via MTOR 1
temsirolimus, vinorelbine ditartrate MTOR SSL via MTOR 1
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 MTOR SSL via MTOR 1
carfilzomib PSMB6 SSL via PSMB6 yes 0
carfilzomib PSMB7 SSL via PSMB7 yes 0
ixazomib PSMB6 SSL via PSMB6 yes 0
ixazomib PSMB7 SSL via PSMB7 yes 0
ixazomib citrate PSMB6 SSL via PSMB6 yes 0
ixazomib citrate PSMB7 SSL via PSMB7 yes 0
perhexiline MTOR SSL via MTOR yes 0
perhexiline maleate MTOR SSL via MTOR yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.